Collaboration with Janssen and Eli Lilly to address lack of paediatric medications
Pharmaceutical Technology
JANUARY 23, 2023
Therefore, with an inadequate or loss of response to these anti-TNFs, clinicians must prescribe adult therapies off-label to treat younger patients. In addition to Skyrizi’s recent supplementary CD indication, both Tremfya and Skyrizi received US FDA approval in psoriasis in 2017 and in 2019, respectively.
Let's personalize your content